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Introduction of Assessment Indicators 
of Lung Cancer Management Proposed 
by Health Insurance Review and 
Assessment Service of Korea
1. Organization of lung cancer specialists
This indicator is to assess the composition of the medical 
staff involved in the lung cancer care in the institutions to be 
evaluated (Table 1). It aims to improve the coordination and 
increase opportunities from various perspectives for patients’ 
care. It is fulfilled when the staffs were consisted of at least one 
member of the pulmonary medicine, hemato-oncology, tho-
racic surgery, pathology, radiation oncology, radiology, and 
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nuclear medicine.
2. Records of smoking history
This indicator is for the physician’s written record on 
smoking and pack-years (PYs) before treatment. The ratio of 
smoking record of patients who is treated with lung cancer is 
calculated as follows: Number of patients with smoking his-
tory/Number of patients treated with lung cancer (surgery, 
chemotherapy, or radiation therapy)×100.
Smoking is not only a major risk factor for lung cancer, but 
PY is also useful for predicting postoperative complications 
related to decreased lung function and mucociliary clearance. 
In addition, preliminary information on the PY of the patient 
before surgery is important to plan the treatment modality 
including surgery, so it is important to identify and record the 
smoking history and PY before treatment. 
3. Records of performance status
This is a measure of the proportion of patients who have an 
assessment of their performance status (PS) before treatment 
before surgery, chemotherapy, or radiation therapy for lung 
cancer. The ratio of performance status record is calculated 
as follows: Number of patients with a record of performance 
status before treatment/Number of patients treated with lung 
cancer (surgery, chemotherapy, or radiation therapy)×100.
This is admitted when the performance status was recorded 
by the medical staff before the treatment modality, including 
surgery for pediatric wedge resection, chemotherapy, che-
motherapy, radiation therapy, chemotherapy combined with 
chemotherapy (CCRT) using the Eastern Cooperative Oncol-
ogy Group (ECOG), World Health Organization (WHO), or 
Karnofsky scoring system described in Table 2.
Table 1. Appropriateness indicators of lung cancer management by HIRA of Korea
Category Area Evaluation index
Structure (1) Treatment ability 1. Organization of lung cancer specialists
Process (19) Diagnostic assessment and completeness 
of medical records (5)
2. Records of smoking history
3. Records of performance status
4. Detailed examination before treatment
5. Records of cancer stage by clinicians
6. Pathologic confirmation before treatment
Surgery (2) 7. Completeness of pathology report
8. Dissection or sampling of lymph nodes
Systemic treatment (8) 9. Consent before chemotherapy
10. Use of flow sheet
11. No chemotherapy in stage IA NSCLC patients
12. Adjuvant chemotherapy within 8 weeks after surgery
13. Use of antiemetics
14. CCRT in LD-SCLC
15. Assessment of AEs
16. Periodic tumor response evaluation during chemotherapy in patients with 
stage IIIB/IV NSCLC
Radiotherapy (4) 17. Records for radiation therapeutic parameters
18. Recordings of AEs during definitive radiotherapy and electrical portal imaging
19. Tumor response and evaluation of the AEs within 2 months after definitive 
radiotherapy
20. The rate of CCRT in unresectable stage III NSCLC patients
Results (2) 21. Mean hospital days
22. Mean cost during hospitalization days
HIRA: Health Insurance Review and Assessment Service; NSCLC: non-small cell lung cancer; CCRT: chemotherapy combined with chemo-
therapy; LD: limited disease; SCLC: small cell lung cancer; AE: adverse events.
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4. Detailed examination before treatment
This index refers to the percentage of patients who under-
went close-up screening examination for lung cancer before 
treatment including surgery, chemotherapy, or radiation 
therapy (Table 3). These include (1) chest computed tomog-
raphy (CT) that includes upper abdomen and adrenal glands; 
(2) positron emission tomography (PET)-CT/PET in the stage 
IB–III non-small cell lung cancer (NSCLC) patients; (3) brain 
CT or brain magnetic resonance image (MRI) in the limited 
disease (LD)–small cell lung cancer (SCLC) and stage II-III 
NSCLC patients; (4) lung function test in the patients who un-
derwent lung cancer surgery and definitive radiation therapy; 
(5) mediastinoscopy and endobronchial ultrasound-guided 
transbronchial needle aspiration or video-assisted thoraco-
scopic surgery in N2 NSCLC patients (excluding stage IV); and 
(6) epidermal growth factor receptor (EGFR) mutation test 
(monitoring) in the stage IV lung adenocarcinoma patients1. 
Prior to treatment, it is essential to perform highly sensitive 
tests to determine the status of patients and the lung cancer 
stage2,3. (1) Chest CT is an indispensable tool for assessment 
of tumor size, location, and involvement with surrounding 
organs, and lymph node4. (2) PET-CT or PET is useful for 
determining metastatic disease2. (3) Brain CT or brain MRI 
is useful for confirming the presence of brain metastases5,6. 
(4) Pulmonary function tests (forced expiratory volume in 1 
second [FEV1], diffusion lung capacity for carbon monoxide) 
are helpful in assessing the risk associated with surgery or 
radical radiotherapy7-9. (5) Mediastinoscopy, endobronchial 
ultrasound, and mediastinal lymph node dissection should 
be performed prior to treatment for mediastinal staging if N2 
stage is suspected because mediastinal stage has a significant 
effect on treatment decisions and prognosis10-12. (6) In NSCLC 
patients who are not candidate of curative therapy, EGFR 
mutation test should be performed because EGFR tyrosine 
kinase inhibitors improve response rates, time to progression, 
and overall survival compared with systemic chemotherapy 
in patients harboring activating EGFR mutation13,14. In case all 
the relevant tests are been carried out, this Indicator is consid-
ered to fulfill the requirement. When the examinations were 
carried out by other institute(s), including an external agency, 
it would be recognized when there is corresponding inspec-
tion films or result sheets. Regarding the chest CT, it should 
be taken within 60 days from the starting day of treatment 
and should include epigastrium and adrenal gland. If there is 
a written description on the epigastrium and adrenal gland, it 
is acknowledged and in this case, the reading findings for the 
upper abdomen should be provided. In case that chest CT 
scan does not include epigastric and adrenal glands, it would 
be acknowledged when PET-CT/PET or abdominal CT scan 
identifies these regions. Regarding pulmonary function tests, 
FEV1 alone is accepted when FEV1 is equal or more than 80% 
Table 2. ECOG/WHO scoring system and Karnofsky PS status scale
ECOG/WHO score system (0–5) Definition Karnofsky score
0 Fully active, able to carry on all pre-disease activities without restriction 90–100
1 Restricted in physically strenuous activity but ambulatory and able to carry out 
work of a light or sedentary nature
70–80
2 Ambulatory and capable of all self-care but unable to carry out any work activities; 
up and about more than 50% of waking hour
50–60
3 Capable of only limited self-care, confined to bed or chair 50% or more of waking 
hours
30–40
4 Completely disabled; cannot carry on any self-care; totally confined to bed or chair 10–20
5 Dead
ECOG: Eastern Cooperative Oncology Group; WHO: World Health Organization; PS: performance score.
Table 3. Radiologic tests and their evaluation subjects in patients with lung cancer
Radiologic test Evaluation subject
Chest CT including upper abdomen/adrenal glands (within 60 days from beginning of initial treatment) All patients diagnosed as lung cancer
PET or PET-CT Stage IB–III NSCLC
Brain CT or MRI LD-SCLC
Stage II, III NSCLC
CT: computed tomography; PET: positron emission tomography; NSCLC: non-small cell lung cancer;  MRI: magnetic resonance image; LD: 
limited disease; SCLC: small cell lung cancer.
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of reference value and there are no abnormal symptoms such 
as dyspnea. EGFR mutation test is recognized if it is confirmed 
before the start of treatment and in case of radiation therapy 
on the metastatic lesion, the test after radiotherapy would be 
accepted.
However, when the patient who does have any lung cancer 
related diagnosis underwent emergency surgery, the patient 
refused examination except chest CT, brain CT/brain MRI, 
and pulmonary function test, and patient status is too poor to 
take examination, it is excluded from evaluation. In addition, 
if the EGFR mutation test is not performed due to insufficient 
specimen, this case shall be excluded from the evaluation by 
including the reason for exclusion such as the pathologic or 
the doctor’s medical records. 
5. Records of cancer stage by clinicians
Clinical cancer stage is assessed by the ratio of complete 
records of pretreatment stage by clinicians to all lung cancer 
patients underwent any treatment modality. For the clinical 
staging, clinicians should describe the records before treat-
ment using TNM staging system according to the American 
Joint Committee on Cancer (7th edition) for NSCLC and a 
two-stage classification (LD or extensive disease [ED]) or 
TNM staging system for SCLC. In patients who underwent 
nonsurgical treatment, pretreatment staging should be re-
ported by one of clinicians including pulmonologist, oncolo-
gist, thoracic surgeon, and radiation oncologist. In patients 
who underwent surgical treatment, thoracic surgeon could 
document complete records of clinical stage within 28 days 
after surgery. In cases of neoadjuvant treatment prior to sur-
gery, clinicians (pulmonologist, oncologist, thoracic surgeon 
or radiation oncologist) must document clinical stage before 
surgery. When the institution shares staging records among 
clinicians or the trainee documents the clinical cancer stage 
in a teaching hospital, the final signature by a corresponding 
specialist is accepted for the evaluation.
6. Pathologic confirmation before treatment
Pretreatment confirmative diagnosis is evaluated by the 
proportion of patients with pretreatment pathological diag-
nosis out of total lung cancer patients who underwent non-
surgical treatment. Referral patients who have only pathology 
reports from outside hospital are also included. Stage IV lung 
cancer patients with palliative radiation therapy are excluded.
7. Completeness of pathology report
Completeness of surgical pathology report is assessed by 
the ratio of complete pathology reports to all surgically re-
sected lung cancer specimens. Surgical specimens requested 
to the referral hospitals for pathologic examination are also in-
cluded. Every complete pathology report should document all 
essential pathological data that will affect patient’s treatment 
and outcome and pathologists signature. Essential pathologic 
data include tumor site, tumor size, histologic tumor type ac-
cording to the WHO classification, visceral pleural invasion, 
lymphovascular invasion, perineural invasion, pathologic 
staging, lymph node status, surgical resection margin status, 
and nonneoplastic pathologic pulmonary findings such as 
interstitial pulmonary fibrosis and tuberculosis. For the patho-
logic staging, each T and N factor must be clearly defined (e.g., 
pT2N2 and pT2Nx). Lymph node state should be reported as 
the number of lymph nodes involved and the total number of 
lymph nodes submitted. Despite of no residual tumor, lymph 
node status and nonneoplastic pulmonary findings are re-
quired. The reason for missing pathologic parameters should 
be documented for the complete report.
8. Dissection or sampling of lymph nodes
This index is defined as the proportion of patients under-
went lymph nodes dissection or sampling out of all surgically 
resected lung cancer patients. Systemic mediastinal lymph 
node dissection or sampling is recommend for complete 
resection because it discovered pathologic N2 involvement 
in 24% of patients with clinical stage I and II NSCLC15. For 
patients undergoing sublobar resection (segmentectomy or 
wedge resection), the appropriate N1 and N2 lymph node sta-
tion should be sampled unless not technically feasible16. In pa-
tients with N2 disease, more than three ipsilateral mediastinal 
lymph node stations should be dissected during surgery15,17. 
N2 disease is based upon the clinical cancer stage by thoracic 
surgeon. The patients with (1) postoperative stage IIIB or IV, (2) 
limited cardiopulmonary function (e.g., chronic obstructive 
pulmonary disease), (3) inaccessible lymph node less than 
three stations due to prior surgery, (4) documented reasons 
for missing lymph node dissection or sampling, (5) pure ad-
enocarcinoma in situ or minimally invasive adenocarcinoma, 
and (6) ground glass opacity on chest CT are excluded. 
9. Consent before chemotherapy
This Indicator refers to the percentage of patients who have 
provided a written statement on the chemotherapy to the 
patient or family member who received chemotherapy and 
who have a consent record. The ratio of patient (or family) 
agreement for chemotherapy is calculated as follows: Number 
of patients with a record of agreement with the description 
of chemotherapy/Number of patients treated with chemo-
therapy×100. The patient and physician should discuss the 
positive effects and possible risks of the chemotherapy and 
the discussion should include the evidence of treatment, treat-
ment related complications and patient’s choice according 
to the prognosis. This indicator is admitted when there is a 
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written consent signed by a doctor who provides sufficient 
explanation for the chemotherapy and if the nurse is on the 
job, the doctor’s final signature is required. The purpose of the 
chemotherapy, the type of chemotherapeutic agents, the time 
or duration of the chemotherapy, and the main side effects 
should be included. Finally, a written consent form is issued 
prior to the initiation of chemotherapy, and a new consent 
form must be filled out whenever the regimen is changed.
10. Use of flow sheet
This index is the percentage of lung cancer patients who re-
ceived chemotherapy using a flow sheet. The ratio of patients 
using flow sheet among lung cancer patients who received 
chemotherapy is calculated as follows: Number of patients 
using flow sheet/Number of patients treated with chemother-
apy×100.
By using flow sheet on the chemotherapy, accurate record-
ing of chemotherapy and monitoring patient status can fa-
cilitate patient status assessment and patient education. This 
flow sheet should include both oral and parenteral anticancer 
drugs, excluding oral target drugs, and include five main items 
such as the purpose of chemotherapy, type of chemotherapy, 
number of cycles, duration, blood counts such as white blood 
count or absolute neutrophil count, hemoglobin, and plate-
let. However, patients with institutional review board (IRB)-
approved clinical trials are excluded from the evaluation. 
11. No chemotherapy in stage IA NSCLC patients
This index refers to the percent of the stage IA lung cancer 
patients who had not received adjuvant chemotherapy, and it 
reflects that the adjuvant chemotherapy is not recommended 
for the stage IA patients. The ratio of patients who do not 
receive chemotherapy (stage 1A) is as follows: Number of 
patients who do not receive adjuvant chemotherapy/Number 
of patients who underwent resection with lung cancer (stage 
1A)×100.
In the cases who did not receive prior therapy, the parame-
ter is evaluated for the cancer staging recorded by the thoracic 
surgeon after surgery, and the cases who have undergone 
preoperative therapy, it is evaluated based on the clinical can-
cer stage recorded by a specialist who is in charge of the pre - 
treatment. However, patients with IRB-approved clinical trials 
are excluded from the evaluation. 
12. Adjuvant chemotherapy within 8 weeks after surgery
This indicator refers to the percentage of patients who un-
derwent first adjuvant chemotherapy within 8 weeks of the 
last therapeutic intervention among patients who underwent 
surgery for stage II/IIIA of NSCLC (<70 years old, ECOG 0–1). 
The ratio of adjuvant chemotherapy within 8 weeks after sur-
gery is calculated as follows: Number of patients who under-
went adjuvant chemotherapy within 8 weeks after surgery/
Number of patients who underwent surgery for stage II/IIIA of 
NSCLC (<70 years old, ECOG 0–1)×100.
Stage II/IIIA patients with NSCLC are required to adjuvant 
chemotherapy after surgery and it is recommended to per-
form adjuvant chemotherapy within 8 weeks considering the 
period of recovery from surgery and surgical complications. 
Exclusion criteria of this indicator (the ratio of adjuvant che-
motherapy within 8 weeks after surgery) are as follows: (1) 
patients who were transferred to other institutions within 8 
weeks after surgery or died, (2) patients who underwent pre-
operative therapy, (3) patients who underwent postoperative 
chemoradiotherapy or only palliative therapy, (4) patients 
who scheduled postoperative radiation therapy for adjuvant 
therapy, (5) patients with IRB-approved clinical trials.
Regardless of dosage regimen, all administered (oral or par-
enteral) chemotherapeutic agents are included in this Indica-
tor. Cancer staging is based on the following criteria: (1) clini-
cal cancer stage recorded by physician before neoadjuvant 
chemotherapy, (2) cancer stage recorded by thoracic surgeon 
after surgery when the patients did not receive neoadjuvant 
chemotherapy. PS is based on the records that were evaluated 
before the start of adjuvant chemotherapy.
13. Use of antiemetics
This index is the proportion of patients provided with a 
serotonin antagonist among those who received moderate-
to-moderate risk emetogenic chemotherapeutic agents. The 
patients who underwent emetogenic chemotherapy of mod-
erate to high risk may suffer nausea and vomiting at least 4 
days and should be protected during periods of risk. It will be 
evaluated the percentage of the patients who provided anti-
emetic agents before administration of chemotherapeutic 
agents with moderate to severe nausea and vomiting. How-
ever, patients with IRB-approved clinical trials are excluded.
14. CCRT for patients with LD-SCLC
This Indicator is the rate of patients who underwent concur-
rent CCRT in LD-SCLC. The PS is based on the records that 
were evaluated before the start of CCRT and the score of the 
PS should be 0–218. Radiation therapy should be given when 
chemotherapy begins one to three cycles, and the combined 
use of radiotherapy and chemotherapy should be performed 
within 1 day19,20.
15. Assessment of adverse effects 
This is an indicator for the percentage of cases who received 
chemotherapy for lung cancer and had an assessment of the 
side effects of chemotherapy before each treatment cycle. As-
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sessment of adverse reactions to chemotherapeutic agents 
such as non-hematologic toxicity (nausea/vomiting, diarrhea, 
systemic asthenia, skin rash, peripheral neuropathy, etc.), 
nephrotoxicity, hepatotoxicity and bone marrow suppression 
are recommended before administration of chemotherapy. 
However, cases that do complete one cycle after the onset of 
chemotherapy and IRB-approved clinical trials are excluded. 
Regardless of oral or parenteral regimens, all assessments of 
the adverse effect should be included and approved by the 
physician if the anticancer drug side-effects are listed on the 
medical record, including flow sheet, before each cycle. When 
evaluating side effects, one or more side effects should be in-
dicated and if there are no side effects, it should be indicated 
as “None.” If oral anticancer drugs are administered alone, 
side effects should be evaluated every cycle within the first 
3 months of administration, and every two to three cycles or 
every 2 to 3 months after 3 months of administration.
16. Periodic tumor response evaluation during 
chemotherapy in patients with stage IIIB/IV NSCLC
Physician should record periodic tumor response evalua-
tion during chemotherapy in patients with NSCLC of stage 
IIIB/IV. They should describe tumor response as complete 
remission (CR), partial response (PR), stable disease (SD), 
or progressive disease (PD) according to WHO or Response 
Evaluation Criteria In Solid Tumor (RECIST) criteria. Tumor 
response assessment should be done every two to three 
cycles or every 2 to 3 months. The lung cancer stage is based 
on the clinical cancer stage recorded by the specialist before 
the initiation of chemotherapy. Tumor response assessment 
methods are used by imaging modalities such as chest X-ray, 
CT, MRI, and PET-CT, etc.
17. Records for radiation therapeutic parameters
There should be a record of the therapeutic radiation pa-
rameters as follows: total radiation dose, radiation dose per 
fraction (or a number of the fraction), and treatment site.
18. Recordings of adverse events during definitive 
radiotherapy and electrical portal imaging
The radiation oncologists usually interview patients who 
receive radiotherapy once a week in the course of treatment 
to evaluate the side effects of radiotherapy. This Indicator is 
used to evaluate whether the side effects and the accuracy of 
the radiation field placement using electronic portal imaging 
devices (EPID). The radiation oncologist must record once a 
week, and a delay of 1–2 days due to holidays or other reasons 
is possible. If there is EPID checklist in the picture archiving 
and communication system, the documents accepted as chart 
records.
19. Tumor response and evaluation of the adverse 
events within 2 months after definitive radiotherapy
Radiation oncologists must record and should describe 
tumor response as CR, PR, SD, or PD according to WHO or 
RECIST criteria. If there is no side effect, it should be recorded 
as “None.”
20. The rate of CCRT in unresectable stage III NSCLC 
patients
This indicator is the rate of patients who underwent CCRT 
in unresectable stage III NSCLC. Radiotherapy should be 
performed on the thoracic lesion and should be performed 
on the same day as chemotherapy21,22. The PS is based on the 
records that were evaluated before the start of CCRT and the 
score of the PS should be 0–123. The age of the patient should 
be less than 70 years.
21. Mean hospital days
This index refers to the average length of hospital stay for 
patients who underwent surgery for lung cancer. The cases 
where the number of hospitalization day exceed the upper 
value or fall below the lower value are excluded and the for-
mula is as follows.
Upper limit=X > [Q3+2.5|Q3-Q1|], Lower limit=X < [Q1-
2.5|Q3-Q1|]
X: total medical expenses or length of hospitalization days, 
Q1: 1st quartile, Q3: 3rd quartile
22. Mean cost during hospitalization days
This indicator is the average cost of patients who are hospi-
talized for lung cancer surgery. This index also excludes the 
cases whose hospitalization days are extremely high or low 
and therefore exceed the upper limit or fall below the lower 
limit. The definitions for the upper and lower values are the 
same as those described in the indicator 21.
Results for Assessment in Lung Cancer 
in Korea24
1. Subjects used for evaluation
Final subjects used for evaluation were 10,350 cases from 
123 institutions. A total of 7,247 cases from 123 institutions 
were subjects used to evaluate “Process Index.” Of these in-
stitutions, tertiary general hospitals and general hospitals ac-
counted for 97.6%. A total of 5,720 cases from 104 institutions 
were subjects used to evaluate “Results Index,” including 4,542 
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cases from 43 tertiary general hospitals and 1,178 cases from 
61 general hospitals. Detailed proportions of subjects used for 
evaluation in terms of institution and index are summarized 
in Table 4.
In terms of treatment modalities, 50.4%, 34.1%, and 15.5% of 
cases underwent surgery, chemotherapy, and radiotherapy, 
respectively. Male cases accounted for 69.7%. Those who were 
60 years old or more accounted for 74.1% of cases. NSCLC 
cases accounted for 82.5% while SCLC cases accounted for 
17.5%. Of 5,981 NSCLC cases, 1,777 (29.7%), 505 (8.4%), 1,087 
(18.2%), and 2,612 (43%) cases were at stages 1, 2, 3, and 4, 
respectively. Among 1,243 SCLC cases, 369 (29.7%) cases had 
LD-SCLC while 874 (70.3%) had ED-SCLC.
2. Results of evaluation
1) Structural category
This evaluation category consisted of one index: “constitu-
tion of specialists.” It indicated whether an institution had all 
required specialists for lung cancer diagnosis and treatment, 
including pulmonologist, oncologist, thoracic surgeon, pa-
thologist, radiation oncologist, radiologist, and nuclear medi-
cine specialist. Fulfillment rates of this index in tertiary general 
hospitals, general hospitals, and clinics were 99.6%, 81.2%, and 
14.3%, respectively. Radiologist showed the highest fulfillment 
rate (100%) while radiation oncologist showed the lowest ful-
fillment rate (69.8%). Distribution of specialists according to 
different types of institutions is shown in Figure 1.
2) Process category
Process category consisted of four areas and 19 indexes. 
“Area of diagnostic assessment and completeness of medical 
records” consisted of five indexes: “Record of smoking history,” 
“Record of performance status,” “Detailed examination before 
treatment,” “Record of cancer stage by clinicians,” and “Patho-
logic confirmation before treatment.” Fulfillment rates for 
these five indexes were 99.7%, 99.7%, 97.0%, 99.5%, and 99.7%, 
respectively. “Area of surgery” consisted of two indexes: “Com-
pleteness of pathology report” and “Dissection or sampling of 
lymph nodes.” The two indexes also showed high fulfillment 
rates (99.6% and 99.8%, respectively).
“Area of systemic treatment” included eight indexes: “Con-
sent before chemotherapy,” “Use of flow sheet,” “No chemo-
therapy in stage IA,” “Adjuvant chemotherapy within 8 weeks 
after surgery,” “Use of antiemetics,” “CCRT in LD-SCLC,” 
“adverse events (AEs),” and “Regular response evaluation for 
stage IIIB/IV NSCLC.” These eight indexes also showed high 
fulfillment rates (99.5%, 99.7%, 99.3%, 97.5%, 99.7%, 96.0%, 
99.7%, and 99.9%, respectively). “Area of radiotherapy” con-
sisted of four indexes: “Records for radiotherapy,” “Assessment 
of AEs during curative radiotherapy and regular image cali-
Table 4. Distribution of subjects used for evaluation
Institution 
Subjects used for evaluation
All Process Index* Results Index
Institution Case Institution Case Institution Case
All 123 (100) 10,350 (100) 123 (100) 7,247 (100) 104 (100) 5,720 (100)
Tertiary general hospital 43 (35.0) 7,373 (71.2) 43 (35.0) 4,579 (63.2) 43 (41.3) 4,542 (79.4)
General hospital 77 (62.6) 2,974 (28.7) 77 (62.6) 2,665 (36.8) 61 (58.7) 1,178 (20.6)
Hospital 2 (1.6) 2 (0.1) 2 (1.6) 2 (0.0) - -
Clinic 1 (0.8) 1 (0.0) 1 (0.8) 1 (0.0) - -
Values are presented as number (%).
*If an institution had less than 150 cases, the evaluation was made for all subject cases. If an institution had more than 150 cases, the evalua-
tion was made for those sampled from subject cases.
Figure 1. Distribution of specialists according to different types of 
institutions. Radiologist showed the highest fulfilment rate (100%) 
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bration,” “Response and AE evaluation within 2 months after 
curative radiotherapy,” and “CCRT for inoperable stage III 
NSCLC.” These four indexes also showed high fulfillment rates 
(99.9%, 99.2%, 99.6%, and 94.2%, respectively).
3) Results category
This category consisted of two indexes: mean hospital days 
and mean cost during hospitalization. Mean hospital days of 
all subject cases were 11.6 days. Those for tertiary general hos-
pitals and general hospitals were 10.5 and 16.3 days, respec-
tively. Mean cost during hospitalization was 9,944,000 won 
($8,891). It was 9,738,000 won ($8,707) for tertiary general 
hospitals and 10,810,000 won ($9,665) for general hospitals. 
Fulfilment rates of different types of institutions for 22 indexes 
are summarized in Table 5.
4) Composite score and grade
To grade subject institutions according to the degree of ful-
fillment, Composite Score for each institution was calculated. 
Subjects used for Composite Score calculation were from 89 
institutions with more than 10 cases. “Composite Score” was 
calculated based on the weight of each “Area” as followings: 
21 for “Treatment ability” (1 index), 18 for “Diagnostic assess-
ment and completeness of medical records” (5 indexes), 10 for 
“Surgery” (2 indexes), 32 for “Systemic treatment” (8 indexes), 
16 for “Radiotherapy” (4 indexes), and three for “Results” (1 
index).
The mean composite score for all subject institutions was 
97.47 points; 99.16 points for tertiary general hospitals and 
95.96 points for general hospitals. A total of 80 institu tions 
(89.9%) were grade 1, which means 95 or higher of composite 
score and all tertiary general hospitals (42 institutions) fell into 
grade 1.
These evaluation results mentioned above were given to 
each subject institution. The report is available at the website 
of Health Insurance Review and Assessment Service (HIRA; 













Structure (1) Treatment ability 1 86.1 99.6 81.2 21.4 14.3
Process (19) Diagnostic assessment and com-
pleteness of medical records
2 99.7 100.0 99.3 0.0 0.0
3 99.7 100.0 99.1 100.0 100.0
4 97.0 97.6 95.9 100.0 100.0
5 99.5 99.9 98.9 100.0 100.0
6 99.7 99.9 99.5 50.0 0.0
Surgery 7 99.6 99.9 98.9 - -
8 99.8 99.8 100.0 - -
Systemic treatment 9 99.5 100.0 98.8 50.0 100.0
10 99.7 100.0 99.3 50.0 100.0
11 99.3 99.9 98.1 - -
12 97.5 97.3 98.0 - -
13 99.7 99.8 99.6 0.0 -
14 96.0 96.7 94.9 - -
15 99.7 100.0 99.2 100.0 100.0
16 99.9 100.0 99.7 100.0 -
Radiotherapy 17 99.9 100.0 99.6 - -
18 99.2 99.5 98.7 - -
19 99.6 99.6 99.6 - -
20 94.2 93.9 94.7 - -
Results (2) - 21 11.6 days 10.5 days 16.3 days - -
22 9,944* 9,738* 10,810* - -
*Thousands of won.
Qualitative assessment of lung cancer management by HIRA
https://doi.org/10.4046/trd.2017.0112 27www.e-trd.org
http://www.hira.or.kr). In addition, institutions with fulfillment 
rate in specific indexes or low grades were recommended to 
make efforts to improve their quality of lung cancer manage-
ment based on this requirement.
Conclusion
In the qualitative assessment of lung cancer management 
by HIRA, it was confirmed that management and treatment 
by majority of hospitals fulfilled assessment indicators.  The 
development of new indicators and feedback of results will be 
of great help in maximizing the effectiveness of treatment at 
the frontline medical fields.
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